SGI-DNA Launches Cell Engineering Services for Custom Cell Line Development

(LA JOLLA, CA) December 15, 2015- SGI-DNA, a Synthetic Genomics, Inc. (SGI) company, has launched a suite of Cell Engineering Services for generation of custom mammalian cell lines for research use.  Cell lines developed using this service are appropriate for the expression of novel proteins as well as a variety of functional studies, including cell-based assays for compound screening.

The introduction of this service provides research laboratories access to all aspects of SGI’s extensive cell engineering experience for design, development and generation of custom cell lines with novel properties. Unique to this service is the SGI Archetype® software which offers extensive genomic databases, proprietary algorithms, and bioinformatics tool sets to aid design.

For each project, SGI-DNA’s scientific staff collaborates with clients and partners to provide expert insight and develop innovative strategies that leverage their advanced technologies. To ensure reliable data, cell lines developed by SGI-DNA are verified by sequencing and further validated upon customer request. This results in a fully-optimized cell engineering approach designed to alleviate challenges, such as variable protein expression, low product yields, and protein instability.

As part of the development of this service, experienced SGI-DNA scientists have applied their knowledge to a range of projects including:

  • The development of customized strategies for optimized mammalian cell engineering
  • The creation of heterozygous and homozygous knockout or knockin cell types
  • Custom SNP generation
  • Targeted mutation of mammalian cell genomes
  • The generation of  cell lines with custom synthetic DNA encoding novel genes, pathways and expression cassettes
  • The introduction of novel DNA sequences at specific genomic sites

“SGI’s research efforts have greatly expanded our mammalian cell engineering capabilities. This has allowed us to develop innovative approaches to address extremely complex mammalian cell engineering challenges in our collaborations with leading biopharmaceutical partners.” said Sean Stevens, SGI’s leader of Mammalian Synthetic Biology.  “Through SGI-DNA, we can now offer precise cell engineering services which take advantage of our unique combination of proprietary sequence databases, state of the art bioinformatics, and experimental know-how.”

Key advantages of SGI-DNA’s Cell Engineering Service:

  • Generation of novel genotypes through mutations at multiple genomic loci
  • Creation of complex multigenic DNA constructs
  • Combination of expression modulation, various reporter genes, generation of knock-in and knock-out cell lines
  • Minimization of off-target risks through the use of proprietary bioinformatics algorithms
  • Expression of virtually any gene sequence with selection markers of your choice

A key technology behind SGI-DNA’s Cell Engineering Services is the Gibson Assembly® method, developed in 2009 by Dan Gibson and his colleagues at the J. Craig Venter Institute along with Synthetic Genomics. In 2010 this well-established approach was used to create the first fully synthetic cell. Since the commercial introduction of the Gibson Assembly® method to the life science community by SGI-DNA, this method has become a mainstay in many synthetic biology laboratories and has attracted interest from both the academic and commercial life sciences community due to its ease-of-use, robustness, and flexibility.

To request a quote or for more information, please visit www.sgidna.com/cellengineering

All products and services are intended for research use only. Not intended for diagnostic or therapeutic uses.

The Gibson Assembly® method is also available under commercial license. For more information contact us at info@sgidna.com

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers the BioXp™ 3200 System, the world’s first DNA printer, in addition to a comprehensive suite of genomic services, including whole genome sequencing, library design, bioinformatics services, and reagent kits to enable synthetic biology.

Media Contact

Mary Canady, 858-433-4994, mcanady@syntheticgenomics.com

SGI-DNA Launches BioXp™ 3200 System Beta-Testing of a Cloning Module to Provide Scientists the Unprecedented Ability to Synthesize and Clone DNA Virtually Hands-Free

(LA JOLLA, CA) December 3, 2015 – SGI-DNA Inc., a Synthetic Genomics Inc. company, announces the launch of beta-testing of the BioXp™ 3200 System Cloning Module, equipping researchers with the ability to synthesize and clone their DNA with an overnight instrument run. The benchtop BioXp™ System, the world’s first DNA printer, is a genomic workstation that generates high-quality DNA from custom designed reagents. Now, with the introduction of the Cloning Module, the BioXp™ System has the additional capability to assemble and simultaneously deliver up to 24 DNA clones from custom DNA sequences submitted electronically. The launch of this first-of-its-kind module allows researchers the ability to obtain cloned de novo DNA fragments in the laboratory virtually hands-free, further automating and shortening molecular biology work flows without relying on a service company.

Development and release of the BioXp™ System Cloning Module marks the first additional application since our early access release in April of 2015. Integrating Gibson Assembly® technology within the automated BioXp™ System workflow empowers customers with the ability to focus on scientific discovery and analytics by releasing users from traditional hands-on, time‑intensive, tedious DNA cloning methods.

“It’s truly exciting that the technologies we developed for simplifying molecular biology are now being automated by the BioXp™ System,” said Daniel Gibson, Ph.D., Vice President of DNA Technology at SGI. “The cloning module is very important as it will pave the way to help researchers streamline the study of genes and gene families at an unprecedented rate.”

BioXp™ System customers are at the forefront of genomics innovation as it is poised to meet the growing demand for large-scale, automated DNA synthesis and cloning projects of both the academic and commercial life science community.

For more information on the Assembly and Cloning Module of the BioXp™ 3200 System, visit www.sgidna.com.

All products are for research use only and are not intended for diagnostic uses.

The Gibson Assembly® method is also available under commercial license. For more information, contact us at info@sgidna.com

About the Gibson Assembly® Method

The Gibson Assembly® method was developed in 2009 by Dan Gibson, Ph.D., and his colleagues at the J. Craig Venter Institute during the team’s quest to construct the first synthetic cell.  Since its introduction, the Gibson Assembly® method has become a mainstay in many synthetic biology laboratories and has attracted interest from both the academic and commercial life sciences community due to its ease-of-use, robustness, and flexibility.

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc. (SGI), is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial entities. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Hamilton Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, bioinformatics, cell engineering, and plasmid DNA services.

Media Contact

Mary Canady, 858-433-4994, mcanady@syntheticgenomics.com

Synthetic Genomics Inc. Expands Collaborative Research and Development Agreement with Lung Biotechnology PBC, a Subsidiary of United Therapeutics Corporation, to Develop Organs for Transplantation

Lung Biotechnology Makes Additional $50M Equity Investment in SGI

(LA JOLLA, CA (September 22, 2015)—Synthetic Genomics Inc. (SGI), a privately held company developing and commercializing genomic driven advancements in a variety of industries, and Lung Biotechnology PBC, a subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), today announced they have expanded their multi-year research and development agreement to develop transplantation-ready pig organs using synthetic genomic advances. The companies initially focused efforts on lung diseases and will now also include kidney diseases. As part of the agreement, SGI will receive royalties and milestones from the development and commercialization of the organs.

SGI is also announcing an additional $50 million equity investment by Lung Biotechnology.  Financial details were not disclosed.  Lung Biotechnology previously invested $50 million in SGI preferred stock in April, 2014.

“We are excited to expand our collaboration with United Therapeutics with the goal to provide organs to patients in high need,” said Oliver S. Fetzer, Ph.D., CEO of SGI. “The progress on the program to date using SGI’s proprietary cell engineering technology has enhanced our confidence and will now be expanded to an additional transplantable organ.  We look forward to deepening the collaboration with our partner United Therapeutics and to combine our expertise to help these patients.”

United Therapeutics Chairman and Co-CEO Martine Rothblatt, Ph.D. added, “Our expanded collaboration with Synthetic Genomics is significant for applying our growing xenotransplantation science platform to the problem of end-stage renal failure.  Our combined expertise will accelerate our efforts to develop an expanded supply of transplantable kidneys, potentially helping tens of thousands of patients suffering from incurable kidney disease.”

Using unique DNA design, DNA synthesis and genome editing, as well as genome modification tools, SGI will develop engineered primary pig cells with modified genomes. This work will entail modification of a substantial number of genes at an unprecedented scale and efficiency.  United Therapeutics will leverage its xenotransplantation expertise to implant these engineered cells, generating pig embryos which develop and are born with transplantable organs. With the science and technology advances made by the SGI team over the last years, the companies are striving to develop these new methods and advances to create organs that are safe and effective for use in humans.

Treatments for kidney failure include dialysis and transplantation, and there were more than 600,000 people with end-stage kidney disease under treatment in the United States during 2012.  More than 50,000 people are added to the kidney transplant wait list each year with more than 100,000 total awaiting a kidney transplant in the United States. The tremendous shortfall of donor organs, results in only about 17,000 United States kidney transplants annually.
Previous attempts to rectify this shortage with animal organs have failed due to genomic incompatibilities, especially with respect to immune and coagulation systems. The collaboration between Synthetic Genomics and Lung Biotechnology aims to eliminate these genomic incompatibilities.

About Synthetic Genomics Inc. (SGI)

SGI is a privately-held company dedicated to developing and commercializing genomic-driven solutions to address a wide range of global challenges. The company is focused on several key commercialization programs including developing new synthetic DNA products, tools and instruments through its subsidiary, SGI-DNA; new and improved algae based food and nutritional products, and biofuels through its subsidiary Genovia Bio; and synthetically-derived vaccines and anti-microbials through Synthetic Genomic Vaccines Inc. (SGVI), a business unit co-founded with the J. Craig Venter Institute. The company is also developing clean water technologies using microbial fuel cells and is developing sustainable agricultural products through AgraCast, a company co-founded with Plenus S.A. de C.V.  For more information go to: www.syntheticgenomics.com

SGI Media Contact

Heather Kowalski, hkowalski@syntheticgenomics.com, 858-361-0466

SGI-DNA Launches Gibson Assembly® Site-Directed Mutagenesis Kit for Accurate, Robust and Efficient Site-directed Mutagenesis of DNA Fragments

(LA JOLLA, CA) September 1, 2015, 2015- SGI-DNA, a Synthetic Genomics, Inc. company announces the launch of the Gibson Assembly® Site-Directed Mutagenesis Kit which allows researchers to efficiently and accurately perform site-directed mutagenesis on DNA fragments. This kit is the third in SGI-DNA’s Gibson Assembly® portfolio, which empowers life science researchers to substantially increase their ability to build genes, edit them, and study their functions using nucleotide insertions, substitutions, or deletions. The Gibson Assembly® Site-Directed Mutagenesis Kit has been optimized to maximize the number of gene editing studies scientists can perform, as it uses less DNA starting material, accommodates larger DNA fragments, and has a higher efficiency compared to existing kits. More information about SGI-DNA’s Gibson Assembly® kit and reagent portfolio can be found at sgidna.com/gibson-assembly.

The Gibson Assembly® method was developed in 2009 by Daniel Gibson and his colleagues at the J. Craig Venter Institute during the team’s quest to construct the first synthetic cell. Since its introduction to the life science community, the Gibson Assembly® method has become a mainstay in many synthetic biology laboratories and has attracted interest from both the academic and commercial life sciences community due to its ease-of-use, robustness, and flexibility. The Gibson Assembly® Site-Directed Mutagenesis Kit complements the Gibson Assembly® HiFi 1-Step Kit and the Gibson Assembly® Ultra Kit, which have been developed and optimized for robust DNA assembly by SGI-DNA in close collaboration with Daniel Gibson’s research group at Synthetic Genomics.

“I’m pleased that the DNA assembly technologies we developed to build the first synthetic cell can now be used by other scientists to study genes, families, and pathways more completely,” said Dan Gibson. “Molecular biologists can now greatly advance their genomics research by increasing their capacity to study the activities of genes and proteins.”

Starting with a circular or a linear DNA template up to 25 kilobases in length, scientists can now introduce up to 5 site directed mutations in a single round. The Gibson Assembly® Site-Directed Mutagenesis Kit enables researchers to accommodate one or up to five site mutations with efficiencies of 95% and 55% respectively. Only 5 nanograms of DNA starting material is needed with this kit, compared to other commercially available kits that require up to 100 nanograms of DNA. The Gibson Assembly® Site-Directed Mutagenesis Kit is available in 2 sizes: 5 reactions (starter kit) and 10 reactions.

For more information on the Gibson Assembly® Site-Directed Mutagenesis Kit, please visit www.sgidna.com/sdm-kit

All products are intended for research use only. Not intended for diagnostic uses.

The Gibson Assembly® method is also available under commercial license. For more information contact us at info@sgidna.com

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services.

Media Contact

Mary Canady, 858-433-4994, mcanady@syntheticgenomics.com

SGI-DNA Receives Frost & Sullivan 2015 North American Synthetic Biology New Product Innovation Award for the BioXp™ 3200 System

(LA JOLLA, Calif.) – August 4, 2015 – SGI-DNA, a Synthetic Genomics, Inc. (SGI) company, was recently recognized by Frost & Sullivan for its groundbreaking innovation in genomic technologies for the BioXp™ 3200 System,  an instrument with the capacity to simultaneously build 32 unique, double-stranded DNA fragments to study gene function, pathways, and whole genomes. Frost & Sullivan, leveraging over 50 years of experience in partnering with Global 1000 companies, evaluated the BioXp™ System’s new product attributes and customer impact, and awarded SGI-DNA its 2015 North American Synthetic Biology New Product Innovation Award at a ceremony July 16, 2015, in Boston, Mass.

SGI-DNA, a wholly owned subsidiary of SGI, is commercializing technologies, reagents, software, and services around synthetic biology. Founded in 2013 and headquartered in La Jolla, Calif., SGI-DNA commercializes the technologies developed through SGI’s core research and development efforts. Synthetic Genomics is making advancements in various scientific applications, such as vaccine development, agricultural biology, organ transplantation, and alternative food, energy  and chemical source development.

One technology to emerge is the recently launched BioXp™ System, an automated DNA assembly benchtop instrument. The platform fully automates DNA assembly, building genes de novo from sequences. This first-of-its-kind instrument will allow researchers to perform their own gene assembly in-house, a task that previously required outsourcing to services providers. By performing the work in-house, laboratories are able to speed up the workflow, control their project timelines, and ensure the highest accuracy of their DNA constructs. Fully automated, the BioXp™ System provides a simple push-button walk-away workflow, allowing users to focus time and energy on other tasks, and run the instrument overnight.

“SGI-DNA’s BioXp™ 3200 System is a major milestone in the synthetic biology field, allowing users to perform DNA assembly quickly and easily in-house, a task that previously required outsourcing,” stated Frost & Sullivan Senior Industry Analyst Christi Bird. “This innovative instrument will help the biotechnology sector and other labs conducting synthetic biology-based projects to speed up and improve their workflows, leading to faster scientific advancements in their fields. For these reasons, SGI is the ideal recipient of the Frost & Sullivan New Product Innovation Award.”

The award ceremony also included Cisco, GE Healthcare, and IBM Security. Laurence Warden, SGI-DNA’s Vice President, Engineering and Instrumentation, and Nathan Wood, Senior Vice President, Synthetic Genomics & President, SGI-DNA, accepted the award. The SGI-DNA BioXp™ System team has achieved many milestones in 2015, including the manufacture and  installation of multiple instruments for early access customers, including biotechnology companies, government laboratories, and research institutions.

“We are honored to have been recognized for new product innovation by Frost & Sullivan,” said Warden. “This award is very gratifying for the team, who designed the BioXp™ System to match the vision of scientific thought leaders at SGI to provide entirely new and improved workflows for biomedical researchers.”

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Hamilton Smith, Clyde Hutchison, Daniel Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services.

Media Contact

Mary Canady, 858-433-4994, mcanady@syntheticgenomics.com

Synthetic Genomics and Gen9 Sign Licensing Agreement for Synthetic Biology Technology Patents

(LA JOLLA, CA and CAMBRIDGE, MA)–June 11, 2015 – Synthetic Genomics Inc. (SGI), a synthetic biology company advancing and innovating genomic science and technologies for transformative products and solutions, and Gen9 Inc., a pioneer in synthetic biology and leader in the development of scalable technologies for synthesizing and assembling DNA, today announced a strategic licensing agreement to leverage their respective strengths in synthetic biology technology development and commercialization. The agreement provides Gen9 Inc. with a non-exclusive worldwide license to SGI’s Febit intellectual property estate. The financial details of the agreement were not disclosed.

In 2012, SGI purchased from Febit Holding GmbH the worldwide rights to three families of patents and patent applications related to key synthetic genomic technologies. All related know-how, equipment and technical support for implementation, were also purchased. This technology included methods for highly parallelized, low-cost oligonucleotide synthesis and retrieval of sequence-validated DNA.  SGI has been using the Febit technology internally in development of key gene synthesis applications.

“We see great value in the Febit IP for companies like Gen9 to increase efficiencies in their manufacturing platforms for the benefit of their customers,” said Nathan Wood, Synthetic Genomics Senior Vice President and President of SGI-DNA, Reagents and Instruments. “We look forward to working with Gen9 and with other companies who are interested in licensing this important family of synthetic biology technology patents.”

“We are excited to announce this agreement with Synthetic Genomics.  As we continue to develop novel applications that leverage our BioFab® platform, we are always seeking to identify new technologies and collaborate with innovative partners in the synthetic biology field,” said Kevin Munnelly, President and CEO of Gen9.

About Synthetic Genomics Inc. (SGI)

SGI is a privately-held company dedicated to developing and commercializing genomic-driven solutions to address a wide range of global challenges. The company is focused on several key commercialization programs including developing new synthetic DNA products, tools and instruments through its subsidiary, SGI-DNA; new and improved algae based food and nutritional products, and biofuels through its subsidiary Genovia Bio; and synthetically-derived vaccines and anti-microbials through Synthetic Genomic Vaccines Inc. (SGVI), a business unit co-founded with the J. Craig Venter Institute. The company is also developing clean water technologies using microbial fuel cells and is developing sustainable agricultural products through AgraCast, a company co-founded with Plenus S.A. de C.V.  For more information go to: www.syntheticgenomics.com

About Gen9

Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Massachusetts. Visit Gen9 at www.gen9bio.com.
Gen9, GeneBit, GeneByte and BioFab are trademarks or registered trademarks of Gen9, Inc. All other brands may be trademarks of their respective holders.

Media Contacts

SGI: Heather Kowalski, 858-361-0466, hkowalski@syntheticgenomics.com
SGI-DNA: Mary Canady, 858-433-4994, mcanady@syntheticgenomics.com
Gen9: Colin Sanford, 203-918-4347, colin@bioscribe.com

International Gene Synthesis Consortium Forms Not-for-Profit Corporation

New Organizational Structure Will Enable a Diverse Set of Stakeholders to Leverage the IGSC’s Biosecurity Expertise

(MENLO PARK, CA) April 28, 2015 –The International Gene Synthesis Consortium (IGSC), an association of the world’s leading gene synthesis companies, today announced that it has established itself as a not-for-profit U.S. corporation. The move is intended to make it easier for the organization to welcome new members, especially small companies, not-for-profits and academic institutions, so that they may leverage the biosecurity expertise of the IGSC.

Working together with governments, NGOs, law enforcement, the synthetic biology community and other stakeholders, the IGSC aims to safeguard biosecurity and promote the beneficial application of gene synthesis technology. By screening the sequences of ordered genes and vetting customers, IGSC members help to ensure that science and industry realize the many benefits of gene synthesis technology while minimizing risk.

“The IGSC has developed a common protocol for biosecurity screening and devotes resources to leading-edge development of best practices,” said Todd Peterson, Chief Technology Officer of Synthetic Genomics Inc. and current Board Chair of the IGSC. “By establishing a more formal structure for the IGSC, we hope to encourage organizations involved in gene synthesis across the globe to benefit from the biosecurity expertise of our membership.”

The IGSC encourages other gene synthesis companies and institutions with common biosecurity goals to join. IGSC Voting Membership is available to gene synthesis companies while Associate Membership is available to smaller companies, not-for-profit entities and academic institutions.

“The IGSC takes pride in leading the way on biosecurity practice and innovation in the field,” said Tim Conlon, Assistant General Counsel, Capital Markets and International for Integrated DNA Technologies, Inc. and current IGSC Secretary. “A strong investment in strong biosecurity practice now will help to ensure the safe growth of an industry that holds the keys to important technological advances in the coming decades.”

About IGSC

The IGSC was founded in 2009 by the world’s leading gene synthesis companies to advance biosecurity across the industry. The IGSC’s goals are (a) to educate gene synthesis companies and the public regarding sequence and customer screening of synthetic gene orders; (b) to identify and prevent the unauthorized synthesis and sale of inappropriate sequences; and (c) to coordinate development of ongoing best practices. For more information about membership or the IGSC screening process, please visit www.genesynthesisconsortium.org.

# # #

Media Contact

Heather Kowalski: hkowalski@syntheticgenomics.com, 858-361-0466

SGI-DNA Launches the BioXp™ 3200 System Early Access Program

BioXp™ System Provides Scientists with Ability to Create High Quality, Synthetic DNA Fragments; Key to Constructing Synthetic Genes, Gene Pathways and Whole Genomes

(LA JOLLA, CA) April 02, 2015 – SGI-DNA Inc. today announced the launch of the BioXp™ 3200 System Early Access Program giving researchers priority access to this one of a kind, personal DNA work station which delivers high quality synthetic DNA fragments. The BioXp™ Instrument has the capacity to simultaneously build 32 unique double-stranded DNA fragments. It is the first instrument system of its kind and empowers researchers with the ability to produce high quality synthetic DNA fragments virtually hands free.

Daniel Gibson, Ph.D., VP DNA Technology at Synthetic Genomics, Inc. states, “The vision is to evolve this system with greater capabilities by continuing to develop downstream applications for synthetic biology. Over time, the BioXp™ System will allow researchers to focus on experimental design instead of performing many of the tedious tasks of cloning and expression.”

In addition to the opportunity to significantly advance their synthetic biology research, Early Access Program customers will enjoy exclusive perks such as an enhanced level of technical and customer support, including priority treatment of obtaining their constructs whether provided via BioXp™ DNA Assembly reagents or through SGI-DNA’s custom synthesis service that excels in synthesizing long and difficult constructs.

The BioXp™ system utilizes the Gibson Assembly® technology and is coupled with a unique error correction formulation resulting in the synthesis of highly accurate DNA fragments. DNA fragments are ready for many applications including off-line sequencing, cloning, assembly into larger fragments, and expression into RNA and proteins. SGI-DNA’s custom gene synthesis service option provides synthesis of longer and more challenging constructs for all gene synthesis needs for customers.

The Gibson Assembly® method was developed in 2009 by Daniel Gibson, Ph.D., and his colleagues at the J. Craig Venter Institute during the team’s quest to construct the first synthetic cell. Since its introduction to the life science community, the Gibson Assembly® method has become a mainstay in many synthetic biology laboratories and has attracted interest from both the academic and commercial life sciences community due to its ease-of-use, robustness, and flexibility.

For more information on the BioXp™ 3200 System, please visit www.sgidna.com/bxp3200. You may also email your request to info@sgidna.com. SGIDNA is a member of the International Gene Synthesis Consortium. All products are for research use only and are not intended for diagnostic uses.

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc. (SGI), is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Hamilton Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services.

# # #

Media Contact

Heather Kowalski: hkowalski@syntheticgenomics.com, 858-361-0466

SGI-DNA Launches Gibson Assembly® Ultra Kit for Robust, Seamless and Efficient Construction of Synthetic Genes, Genetic Pathways and Whole Genomes

(LA JOLLA, CA) January 21, 2015–SGI-DNA announces the launch of the Gibson Assembly® Ultra Kit which allows researchers to perform complex, large, and multiple fragment assemblies in a simple, two-step reaction.

“With the Gibson Assembly® Ultra Kit, researchers can assemble up to 15 fragments at one time in less than two hours,” says Vibhu Gupta, Senior Product Manager at Synthetic Genomics, Inc. “The kit provides a proprietary enzyme formulation for Gibson Assembly®, allowing researchers to assemble fragments ranging from 100 bp to 100 kb.” “Our goal is to provide researchers with cutting-edge, easy to use, and seamless technology that takes synthetic biology to a whole new level.”

This Gibson Assembly® Ultra Kit is the second kit in SGI’s growing Gibson Assembly® portfolio utilizing the Gibson Assembly® method. The first kit launched was the Gibson Assembly® HiFi 1 Step Kit, a high fidelity formulation that significantly reduces errors/mutations at the cloning junctions, enabling researchers to assemble up to 5 fragments in a one hour, one-step reaction.

The Gibson Assembly® method was developed in 2009 by Dan Gibson, Ph.D., and his colleagues at the J. Craig Venter Institute during the team’s quest to construct the first synthetic cell. Since its introduction to the life science community, the Gibson Assembly® method has become a mainstay in many synthetic biology laboratories and has attracted interest from both the academic and commercial life sciences community due to its ease-of-use, robustness, and flexibility.

The Gibson Assembly® Ultra Kit is available in 3 sizes: 5 reactions (starter kit), 10 reactions and 50 reactions. Mastermixes are sold separately.

For more information on the Gibson Assembly® Ultra Kit, please visit www.sgidna.com/ultra_kit

For more information on the Gibson Assembly® HiFi 1 Step Kit, please visit www.sgidna.com/hifi_kit

All products are for research use only and are not intended for diagnostic uses.

The Gibson Assembly® method is also available under commercial license. For more information contact us at info@sgidna.com

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services.

# # #

Technical Contact

Vibhu Gupta: vgupta@syntheticgenomics.com, 858-433-2288

Media Contact

Heather Kowalski: hkowalski@syntheticgenomics.com, 858-361-0466

SGI-DNA Launches Gibson Assembly® HiFi 1 Step Kit for Simple, Seamless and Rapid Construction of Synthetic Genes, Gene Clusters and Genetic Pathways

LA JOLLA, Calif., Nov. 20, 2014 — SGI-DNA announces the launch of the Gibson Assembly® HiFi 1 Step Kit which allows researchers to assemble multiple, large DNA fragments in a simple one hour, one-step reaction.

This is the first high fidelity kit on the market using the Gibson Assembly® method.  Researchers can now assemble up to 5 fragments, including large constructs (up to 100 kb), in a fast, reliable reaction.

“With the Gibson Assembly® HiFi 1 Step Kit researchers can obtain a perfect clone in their initial attempt,” says Vibhu Gupta, Senior Product Manager at SGI-DNA. “The kit provides a proprietary enzyme formulation for Gibson Assembly® that results in significantly less errors at cloning junctions which is a common challenge for researchers in a variety of disciplines.”

A researcher from the University of California, San Diego, Erna van Niekerk, PhD., comments, “I have tried it with a construct and ran a parallel experiment with a competing kit from another vendor. I picked 3 colonies from the Gibson Assembly® HiFi 1 Step Kit and 3 colonies from the competing product. Three of 3 Gibson clones gave me the right insert. Zero of 3 from competing kit gave me the right insert. Of the 3 Gibson clones: 2 of 3 had the correct sequence both forward and reverse sequencing confirmation and 1 of 3 had an extra nucleotide.”

The Gibson Assembly® method was developed in 2009 by Dan Gibson, Ph.D., and his colleagues at the J. Craig Venter Institute during the team’s quest to construct the first synthetic cell. It uses a one-step, isothermal approach to enable the rapid assembly of oligonucleotides and multiple DNA fragments. Since its introduction to the life science community, the Gibson Assembly® method has become a mainstay in many synthetic biology laboratories and has attracted interest from both the academic and commercial life sciences community due to its ease-of-use, robustness and flexibility. This Gibson Assembly® kit provides researchers SGI’s first commercially available option utilizing the Gibson Assembly® method.

The Gibson Assembly® HiFi 1 Step Kit is available in 3 sizes: 5 reactions (starter kit), 10 reactions and 50 reactions.

For more information on the Gibson Assembly® HiFi 1 Step Kit, please visit www.sgidna.com

All products are intended for research use only. Not intended for diagnostic uses.

The Gibson Assembly® method is also available under commercial license. For more information contact us at info@sgidna.com

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services.

SGI-DNA Technical contact: Vibhu Gupta, Senior Product Manager, 858.433.2288; vgupta@syntheticgenomics.com

Media contact: Heather Kowalski, hkowalski@syntheticgenomics.com; 858-361-0466